Publications by authors named "Ruisi Tang"
HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.
Front Pharmacol
September 2024
Breast cancer (BC) has the second highest incidence among cancers and is the leading cause of death among women worldwide. The human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20%-30% of BC patients. The development of HER2-targeted drugs, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), has improved the operation rate and pathological remission rate and reduced the risk of postoperative recurrence for HER2-positive early-stage BC (HER2+ EBC) patients.
View Article and Find Full Text PDFObjective: To examine the prevalence of cancer-related cognitive impairment (CRCI) and its contributing factors in patients with nasopharyngeal carcinoma (NPC) and explore the relationship between various assessment methods.
Methods: A cross-sectional study was conducted with 367 patients with NPC between March 2022 and April 2024 at Chongqing University Cancer Hospital. The data gathered from the demographic questionnaire, Montreal Cognitive Assessment (MoCA), Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) were analyzed using logistic regression.
Article Synopsis
- * Research indicates that people with CU often have gut dysbiosis, and infections may also contribute to the condition.
- * The main treatment for CU is second-generation non-sedating antihistamines, but their effectiveness has limitations; recent studies suggest new treatment possibilities focusing on gut microbiota and its relationship with existing therapies.